Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 42Neoplasms 14Carcinoma, Hepatocellular 9Gastrointestinal Stromal Tumors 7Liver Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Astrocytoma 2Advanced Cancer 2Wilms Tumor 1Uterine Cervical Neoplasms 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Malignant Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Physician Education 1Pancreatic Neoplasms 1Neuroblastoma 1Melanoma 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1regorafenib 1Trifluridine 1Tablets 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER2 IHC3+ Advanced Colorectal Cancer × regorafenib × Clear all
NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
142 enrolled
Gastrointestinal

HER2 IHC3+ Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡